Since its discovery, the Janus kinase-signal transduction and activation of transcription (JAK-
STAT) pathway has become recognized as a central mediator of widespread and varied …

Major progress has been recently made in understanding the molecular pathogenesis of
myeloproliferative neoplasms (MPN). Mutations in one of four genes—JAK2, MPL, CALR …

The dysregulation of the JAK/STAT pathway drives the pathogenesis of myelofibrosis (MF).
Recently, several JAK inhibitors (JAKis) have been developed for treating MF. Select …

Myelofibrosis is an enigmatic myeloproliferative neoplasm, despite noteworthy strides in
understanding its genetic underpinnings. Driver mutations involving JAK2, CALR or MPL in …

Long noncoding RNAs (lncRNAs) dysregulated in cancer potentially play oncogenic or
tumor-suppressive roles. While the X inactivate-specific transcript (Xist) lncRNA is important …

The principal morbidity and mortality in patients with essential thrombocythemia (ET) and
polycythemia rubra vera (PV) stems from thrombotic events. Most patients with ET/PV harbor …

Despite the identification of driver mutations leading to the initiation of myeloproliferative
neoplasms (MPNs), the molecular pathogenesis of MPNs remains incompletely understood …

Aberrant JAK 2 signalling plays a central role in myeloproliferative neoplasms (MPN). JAK 2
inhibitors have proven to be clinically efficacious, however, they are not mutation‐specific …

Primary myelofibrosis (PMF) is a clonal hematologic malignancy characterized by BM
fibrosis, extramedullary hematopoiesis, circulating CD34+ cells, splenomegaly, and a …

The Philadelphia chromosome negative myeloproliferative neoplasms, including
polycythemia vera, essential thrombocytosis, and myelofibrosis, are driven by hyper …